0001209191-23-052750.txt : 20231012 0001209191-23-052750.hdr.sgml : 20231012 20231012215632 ACCESSION NUMBER: 0001209191-23-052750 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231012 DATE AS OF CHANGE: 20231012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barchas Isaac CENTRAL INDEX KEY: 0001808343 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39580 FILM NUMBER: 231323716 MAIL ADDRESS: STREET 1: 1601 BRYAN STREET, SUITE 4141 CITY: DALLAS STATE: TX ZIP: 75201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunome Inc. CENTRAL INDEX KEY: 0001472012 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770694340 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 665 STOCKTON DRIVE STREET 2: SUITE 300 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 610-321-3700 MAIL ADDRESS: STREET 1: 665 STOCKTON DRIVE STREET 2: SUITE 300 CITY: EXTON STATE: PA ZIP: 19341 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-10-02 0 0001472012 Immunome Inc. IMNM 0001808343 Barchas Isaac C/O IMMUNOME, INC. 665 STOCKTON DRIVE, SUITE 300 EXTON PA 19341 1 0 0 1 See remarks Common Stock 121680 D Common Stock 2712328 I See Footnotes Stock Option (Right to Buy) 1.35 2032-09-26 Common Stock 76885 D Mr. Barchas was appointed to the board of directors of the Issuer effective immediately after the Effective Time (as defined in the Merger Agreement). In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.) and prior to Mr. Barchas being appointed to the board of directors of the Issuer, Mr. Barchas exchanged (i) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer and (ii) his shares of common stock of Morphimmune for shares of the Issuer. As of the date hereof, Arsenal Bridge Venture II, LLC ("ABV II"), Arsenal Bridge Venture II-B, LLC (ABV II-B), RBP Catalyst Fund, L.P. ("RBP Catalyst") and Research Bridge Partners, Inc. ("RBP" and collectively with ABV II, ABV II-B and RBP Catalyst, the "ABV Entities") own 1,471,613 shares of Issuer common stock, 942,768 shares of Issuer common stock, 176,267 shares of Issuer common stock and 121,680 shares of Issuer common stock, respectively, and such shares were acquired prior to Mr. Barchas joining the board of directors of the Issuer. Mr. Barchas was appointed as a member of the board of directors of the Issuer effective immediately after the Closing (as defined in the Merger Agreement). Mr. Barchas (i) is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B, and (ii) as the Chief Executive Officer of RBP, which is the general partner of RBP Catalyst, exercises voting and investment power over the shares held by RBP and RBP Catalyst. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares. In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable. On the basis of the relationship between Mr. Barchas and the ABV Entities, the ABV Entities may be subject to Section 16 of the Exchange Act with respect to the Issuer as so-called directors by deputization. /s/Isaac Barchas 2023-10-12